Retatrutide is an investigational once-weekly injectable medication being developed by Eli Lilly for obesity, type 2 diabetes, and related metabolic diseases. It is not yet FDA-approved and is currently in late-stage (Phase 3) clinical development. What makes it different? Current weight-loss medications target one or two hormone pathways: - Semaglutide (Ozempic/Wegovy): GLP-1 receptor agonist - Tirzepatide (Mounjaro/Zepbound): GLP-1 + GIP receptor agonist - Retatrutide: GLP-1 + GIP + glucagon receptor agonist (a “triple agonist”) The three hormones work together in complementary ways: - GLP-1: Reduces appetite, slows stomach emptying, improves blood sugar. - GIP: Enhances insulin release and appears to boost weight-loss effects when combined with GLP-1. - Glucagon: Increases energy expenditure (burning more calories) and may help mobilize fat stores, although it can also raise blood sugar if used alone. In retatrutide, the GLP-1 and GIP effects help offset that. How effective is it? Retatrutide has produced some of the largest weight-loss results seen with any medication: - In Phase 2 studies, people lost up to about 24% of their body weight after 48 weeks. - More recent Phase 3 trials reported around 28% average weight loss at the highest dose over 80 weeks in adults with obesity without diabetes. For people with type 2 diabetes, weight loss has been somewhat lower (which is common with obesity medications), around 20–21%, while also substantially improving blood sugar control. Side effects The side effects look similar to other GLP-1 medications: - Nausea - Vomiting - Diarrhea - Constipation - Reduced appetite These are usually most noticeable while increasing the dose. Researchers are still studying long-term safety because the glucagon component is relatively new compared with existing GLP-1 drugs. Is it available? No. As of August 2026: - Retatrutide is not FDA-approved. - Lilly has reported positive Phase 3 results and plans to seek FDA approval, but it is currently available only through clinical trials. Health experts advise avoiding products sold online claiming to be retatrutide because they are unapproved and may be unsafe.

✨ THE BEAUTY BLEND: KPV + GHK-Cu 🧬💗 Repair. Rejuvenate. Glow. KPV + GHK-Cu is a popular peptide combination in the skin-research space, pairing two peptides with complementary properties: 🌸 KPV Known for its anti-inflammatory and calming properties and being studied for skin barrier support and repair. ✨ GHK-Cu A copper-binding peptide studied for its role in skin remodeling, collagen and elastin production, wound repair, and overall skin appearance. 💗 Why combine them? The idea behind the blend is simple: KPV helps calm while GHK-Cu helps support the rebuilding and remodeling process. Together, they’re being researched for applications involving skin appearance, irritation, barrier function, and recovery. 🔬 Research topics include: • Skin repair & regeneration • Inflammation & redness • Collagen/elastin support • Skin texture & elasticity • Acne-prone or irritated skin • Overall skin rejuvenation ⚠️ Important: Peptide research is still evolving, and these compounds are not established treatments for skin conditions. Research products should not be assumed to be safe, effective, sterile, or appropriate for human use. 🧪 RESEARCH USE ONLY — NOT FOR HUMAN CONSUMPTION What would you research first with the Beauty Blend — KPV, GHK-Cu, or the combination? 👇🧬

https://youtube.com/playlist?list=PLBSYD0HP9NeG6zyMpn0jQbwbWvkeGoBoO&si=lYaxhHc_M7XrlfYt

Welcome to my educational community on peptide research! 🧬✨ Here, you’ll find easy-to-understand infographics, research information, and educational content about peptides, including their potential benefits and protocols. This is a judgment-free space where you can openly share your experiences, ask questions, and discuss your peptide journey without feeling filtered or judged. As a mom of three with varying needs, and as someone who’s about to turn 40, I’ve personally found peptides to be a fascinating part of my own wellness journey. I created this community to share what I’ve learned, learn from others, and build a supportive space where we can explore the research together. Research. Learn. Share. Support. 🧬💙 For educational and research purposes only. Not medical advice.

KPV = Lysine–Proline–Valine, a short tripeptide derived from the naturally occurring peptide α-MSH (alpha-melanocyte-stimulating hormone). So, what makes KPV interesting? 👇 🔬 Research has focused on: • Inflammatory pathways — particularly pathways involved in regulating inflammatory signaling • Gut & intestinal research — investigated in preclinical models of intestinal inflammation • Skin & barrier function — studied for potential effects on inflammatory skin responses • Immune signaling — researchers are interested in how KPV may influence inflammatory mediators • Oxidative stress — investigated for potential cellular-protective effects Why is KPV often included in peptide blends? KPV is particularly interesting because researchers are exploring its potential anti-inflammatory and tissue-supporting properties without the broader hormonal effects associated with the parent α-MSH molecule. ⚠️ Important: Most KPV research is preclinical, meaning findings from laboratory and animal studies cannot automatically be assumed to work the same way in humans. KPV is not an FDA-approved treatment. Research use only • Not for human consumption